Speaker Profile
M.D., Co-Founder, Executive Chair, ReIGNITE
Biography
David Kirn, MD, is Founder and Executive Chair ReIGNITE, co-founder and CEO of 4DMT, Professor of Bioengineering at UC Berkeley, and board director and co-Founder of the UC Berkeley Life Sciences Entrepreneurship Center.
He was co-founder and CEO of four viral vector-based genetic medicines companies, and senior R&D executive at Onyx and Celgene, and strategic advisor to Novartis, Bayer, Pfizer, Biogen.
He received a BA (Departmental Citation; Phi Beta Kappa) from UC Berkeley, an MD (Alpha Omega Alpha) from UCSF and completed internal medicine residency at Harvard Medical School, Brigham & Women’s Hospital (including term as Chief Medical Resident at affiliated WRVA hospital). He completed medical oncology and clinical research fellowships at UC San Francisco. He was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center, was named to The Medicine Maker Power List, Advanced Medicine in 2022, and was a 2024 PharmaVoice 100 honoree in the Standout Leaders category.
Talk
Will discuss the history of oncolytic virus therapeutics, identifying the limitations for the field, and focusing on next-generation solutions to unlock the full potential of this immunotherapeutic modality for cancer patients.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
